Why Curing Superbugs Keeps Bankrupting the Companies That Make the Cure

Here is one of the strangest paradoxes in modern markets. Antimicrobial resistance — the rise of bacteria, fungi, and other pathogens that shrug off the drugs meant to kill them — is among the largest, most clearly quantified threats to human health and the global economy this century. And yet the handful of companies that actually develop new antibiotics to fight it have a recurring habit: they win FDA approval, launch their drug, and then file for bankruptcy.

That is not a bug in the system. It is the system. And understanding why is the key to understanding where the money will eventually flow.

A threat measured in millions of lives and trillions of dollars

Start with the scale, because it is genuinely staggering. Drug-resistant infections are already associated with roughly 5 million deaths a year. A landmark modeling study published in The Lancet projects more than 39 million cumulative deaths directly attributable to antimicrobial resistance (AMR) between 2025 and 2050 — a death toll on the order of a slow-motion pandemic that never ends.

The economic figures are no less alarming. The World Bank has estimated that AMR could drive $1 trillion in additional healthcare costs by 2050 and impose annual GDP losses of $1 trillion to $3.4 trillion by 2030. The most extensive modeling to date, from the Institute for Health Metrics and Evaluation, warns that superbugs could raise annual global healthcare costs by $159 billion and jeopardize food security for over two billion people by mid-century.

This is the part everyone in public health agrees on. AMR is a top-tier systemic risk — the kind of slow, compounding threat that, like climate change or pension shortfalls, is easy to ignore until it is suddenly unignorable. Modern medicine quietly depends on antibiotics working: routine surgery, chemotherapy, organ transplants, and intensive care all assume infections can be controlled. Take that assumption away and the foundations of 20th-century medicine start to crack.

So you would expect capital to be pouring into the solution. It isn't. And the reason is a textbook case of market failure.

The cure that bankrupts its maker

In 2018, a small biotech called Achaogen won FDA approval for plazomicin (Zemdri), an antibiotic specifically valued for treating carbapenem-resistant infections — exactly the kind of last-line threat the world says it desperately needs weapons against. By the end of that year, the drug had generated about $800,000 in sales. Achaogen had spent roughly $300 million developing it. Less than a year after approval, the company filed for bankruptcy. Its assets — including the drug — were later sold for a fraction of development cost.

Achaogen was not an outlier. In December 2019, Melinta Therapeutics, one of the largest dedicated antibiotics players in the US, filed for Chapter 11 with nearly $1 billion in debt. Tetraphase, Aradigm, and Nabriva all hit the same wall. The pattern is so consistent it has a grim nickname in biotech circles: the "valley of death" for anti-infectives.

Why does saving lives lose money? Because of a brutal commercial logic unique to antibiotics:

• A new antibiotic is, by design, used as little as possible. Responsible "stewardship" means hospitals hold novel drugs in reserve to slow resistance. The better and more important your drug, the less it gets prescribed. No other category of medicine is deliberately rationed by its own buyers.
• Antibiotics are cheap and courses are short. A patient takes a blockbuster cancer or autoimmune drug for years at five- or six-figure annual cost. An antibiotic course lasts days and is priced in the hundreds. There is no recurring revenue.
• Generics crush pricing. The moment a drug class matures, ultra-cheap generics define what hospitals expect to pay, leaving little room for an innovator to recoup R&D.

The result: between 2016 and 2020, venture funding for antimicrobial companies rose just 29%, while biotech funding overall jumped 175%. In the decade ending 2020, 109 oncology-focused companies raised $12 billion — versus roughly $700 million for the dozen biotechs working on antibacterials. Big Pharma has largely walked away; the field has thinned to a few diversified majors and a scattering of fragile small caps.

This is what economists mean when they call antibiotics a "broken market." The social value of the product is astronomical. The private return is negative. Left to ordinary market incentives, the pipeline dries up exactly as the threat accelerates — which is precisely what is happening.

This is where the analysis gets actionable. AlphaBriefing members get the full investment framework — scenarios, positioning, and the bottom line.

Subscribe to AlphaBriefing — Free, Member, and Paid tiers available.